| Abstract | The introduction of TNF-alpha blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in moderately severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments. |
| Authors | Tamás Molnár
(Affiliation: Szegedi Tudományegyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika, Szeged. mot at inlst.szote.u-szeged.hu)
|
| Journal | Orvosi hetilap
(Orv Hetil)
Vol. 150
Issue 38
Pg. 1773-9
(Sep 20 2009)
ISSN: 0030-6002 [Print] Hungary |
| Vernacular Title | TNF-alpha-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben. |
| PMID | 19740722
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- CDP870
- Immunoglobulin Fab Fragments
- Polyethylene Glycols
- Tumor Necrosis Factor-alpha
- adalimumab
- infliximab
|
| Topics |
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Chronic Disease
- Colitis, Ulcerative
(drug therapy)
- Crohn Disease
(drug therapy)
- Humans
- Immunoglobulin Fab Fragments
(pharmacology, therapeutic use)
- Inflammatory Bowel Diseases
(drug therapy, metabolism)
- Polyethylene Glycols
(pharmacology, therapeutic use)
- Severity of Illness Index
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|
